Lyra Therapeutics (LYRA) EBT Margin (2021 - 2025)
Lyra Therapeutics (LYRA) has disclosed EBT Margin for 5 consecutive years, with 23924.0% as the latest value for Q3 2025.
- On a quarterly basis, EBT Margin fell 1783887.0% to 23924.0% in Q3 2025 year-over-year; TTM through Sep 2025 was 3525.91%, a 1015827.0% increase, with the full-year FY2023 number at 4019.32%, up 3534.0% from a year prior.
- EBT Margin was 23924.0% for Q3 2025 at Lyra Therapeutics, down from 4062.84% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 828.15% in Q4 2024 to a low of 129290.91% in Q4 2022.
- A 5-year average of 17262.52% and a median of 4217.67% in 2024 define the central range for EBT Margin.
- Peak YoY movement for EBT Margin: crashed -12426619bps in 2022, then soared 11892173bps in 2023.
- Lyra Therapeutics' EBT Margin stood at 5024.72% in 2021, then tumbled by -2473bps to 129290.91% in 2022, then surged by 92bps to 10369.18% in 2023, then surged by 108bps to 828.15% in 2024, then tumbled by -2989bps to 23924.0% in 2025.
- Per Business Quant, the three most recent readings for LYRA's EBT Margin are 23924.0% (Q3 2025), 4062.84% (Q2 2025), and 4668.31% (Q1 2025).